Physician profile
Leanne Dada
NPI 1386028157
$2,392.13
in general payments reported to CMS, 2019-2025
13 companies · $758 in 2025
The $758 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.05 · 2022: $570 · 2023: $780 · 2024: $232 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $733.88 | 2021-2025 | Krystexxa, Uplizna, Tavneos |
| Horizon Therapeutics Plc | $511.04 | 2022-2023 | Krystexxa |
| Abbvie INC. | $429.93 | 2022-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $319.84 | 2022-2025 | |
| Inspire Medical Systems, INC. | $145.29 | 2024 | Inspire |
| Ucb, INC. | $70.84 | 2025 | Bimzelx |
| Glaxosmithkline, LLC. | $62.97 | 2022-2023 | Benlysta |
| Pharmacyclics LLC, An Abbvie Company | $24.24 | 2023 | Epkinly, Imbruvica |
| Aurinia Pharma U.S., INC. | $21.44 | 2025 | Lupkynis |
| Invivyd INC | $21.40 | 2025 | Pemgarda |
| Astrazeneca Pharmaceuticals Lp | $18.73 | 2025 | Saphnelo |
| Pacira Therapeutics, INC. | $17.34 | 2021 | |
| Genzyme Corporation | $15.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Dada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.